Eli Lilly $960 million acquisition of CoLucid Pharmaceuticals

18/1/2017

Public acquisition

Value:

$ 960 million

Status:

Announced

Date:

18/1/2017

Overview:

Eli Lilly has announced its $960 million acquisition of CoLucid Pharmaceuticals.
CoLucid is in the process of developing oral tablets for the treatment of migraine headaches.
Goldman Sachs acted as financial adviser for Eli Lilly and MTS Health Partners acted as financial adviser for CoLucid.
The deal is expected to close in the first quarter of 2017.

Kurt Stumpo - Journalist

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:

Faegre Baker Daniels

Party: CoLucid Pharmaceuticals (Target)

Weil Gotshal & Manges

Party: Eli Lilly (Acquirer)

Lawyers: Matthew Gilroy, Raymond Gietz

Related deals